Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia.

Trial Profile

Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Citalopram (Primary) ; Reboxetine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2012 Actual initiation date changed from 1 Nov 2008 to 27 Jul 2008 as reported by European Clinical Trials Database.
    • 02 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top